My story on MAP Pharmaceuticals ( MAPP and its inhaled migraine drug Levadex prompted Daryl S. to offer a skeptical take on the drug's commercial prospects. "I am a private practice neurologist and see migraine patients pretty much daily. I am not all that enthusiastic about the prospects for MAP's Levadex for migraine for a couple of reasons. 1. DHE has been around forever, and the newer triptans are really considered the best and safest drugs for migraine. 2. There is already an intranasal DHE (Migranal), which we may use rarely if a patient fails most of the available triptans (8 tablets, 2 orally disintegrating tablets, 2 nasal sprays, and one injectable.) 3. Primary care physicians who see the vast majority of migraine patients will not embrace DHE because they aren't comfortable with potential serious side effects, so prescribers of Levadex would probably only be neurologists who see referral cases.
Next, an email from Jonah: "I've been a long time reader of your posts. I was wondering what you thought of Human Genome Sciences ( HGSI as an investment opportunity? The market cap is only about $250 million despite the fact that the company has income flowing in from Abthrax and potential income coming in next year from Albuferon. Also the Lupus trial results are due in a little more than a month."
The Hostile React-o-Meter blew up Thursday after the posting of my bearish column on Hemispherx ( HEB - Get Report) and its chronic fatigue drug Ampligen. Dozens and dozens of emails poured in, but not a single one contained an intelligent response or answers to the facts, questions and concerns posed. Paul C. (he's a multi-millionaire, he tells me) wrote to threaten me with a lawsuit because I wrote a column that moved the stock. "You should not be writing articles that after they are published makes the stock move in one way or another, this is stock manipulation." Funny, I thought it was journalism. And then, of course, there was the cursing and the name-calling. Lots of cursing. Lots of name-calling. According to my email friends, I'm bald, stupid, evil, ugly, a psycho, a "looser" (people have trouble with this one. It's "loser" not "looser") and a moron. I'm manipulating the stock lower so I can buy more, but I'm also helping my short-selling buddies. I have a personal vendetta against the company. I'm being reported to the SEC, the FTC and various other three-lettered agencies of the federal government. Jim Cramer is my puppet master and he's bald, too. Lastly, I'm Jewish (I love when that one gets tossed onto the pile.) Can't anyone out there come up with an original putdown?
I did receive a handful of thoughtful emails, so all is not lost. Michael R. writes, "Thank you for the write up about Hemispherx. I'm disabled with CFS (and a RealMoney subscriber) and I've followed the Ampligen story with interest for about 15 years. You did an admirable job of writing the history of this drug, and of Hemispherx. It's a complicated story. The drug company has done a terrible job of getting this drug to market, as you detail.